Effect of MicroRNA-26a Targeting mCTGF on Calcification of Vascular Smooth Muscle Cells Through Regulating Osteoprotegerin/Receptor Activator of NF-κB/Receptor Activator of Nuclear Factor Kappa-B Ligand Signaling Pathway

被引:0
|
作者
Zhang, Zhe [1 ]
Cheng, Jing [1 ]
Yang, Zhen [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Cardiothorac Surg, Wuhan Cent Hosp, Wuhan 430014, Hubei, Peoples R China
关键词
VSMCs; OPG/RANK/RANKL; Calcification; MicroRNA-26a; mCTGF; Exosomes; TISSUE GROWTH-FACTOR; INDUCED FIBROTIC RESPONSES; INHIBITION; PROLIFERATION;
D O I
10.1166/jbt.2020.2516
中图分类号
Q813 [细胞工程];
学科分类号
摘要
To explore the effect of microRNA-26a targeting mCTGF on inhibiting the calcification of vascular smooth muscle cells (VSMCs) through OPG/RANK/RANKL signaling pathway. VSMCs were isolated and cultured by adherent method. The morphology of VSMCs was observed under microscope and the surface antigen was identified by flow cytometry. The calcification of VSMCs was detected using alizarin red S staining and oil red O staining. microRNA-26a level in supernatant of cultured VSMCs was detected by ultracentrifugation method. The binding site between microRNA26a and 3'-UTR of mCTGF was predicted by bioinformatics software; VSMCs were induced to be calcified and verified by the luciferase reporter gene assay. The mRNA and protein expressions of OPG/RANK/RANKL signaling pathway were measured by qRT-PCR and Western blotting. Normal VSMCs were assigned into normal group (normal VSMCs were treated with the exosomes secreted by normal VSMCs), CKD group (normal VSMCs were treated with the exosomes secreted by VSMCs in mice with chronic kidney disease (CKD)) and CKD/overexpressed mCTGF group (normal VSMCs were treated with the exosomes secreted by VSMCs in CKD mice and meanwhile treated with overexpressed mCTGF) followed by analysis of OPG/RANK/RANKL signaling level by qRT-PCR and ALP activity. VSMCs grew against the wall and showed a long fusiform shape. Calcification and adipogenesis of VSMCs was found under different induction conditions. microRNA26a level in the supernatant of VSMCs in CKD group was significantly higher than normal group; after microRNA-26a bound to of mCTGF, mCTGF level in the CKD/overexpressed mCTGF group was significantly lower. The expression of OPG/RANK/RANKL signaling pathway was significantly decreased in the CKD/overexpressed mCTGF group. Meanwhile, OPG/RANK/RANKL signaling protein was increased significantly after treatment of exosomes secreted by VSMCs in CKD mice. mCTGF is the target gene of microRNA-26a and microRNA-26a can target mCTGF to regulate exosomes secretion by VSMCs and OPG/RANK/RANKL signaling to inhibit the calcification of VSMCs.
引用
收藏
页码:1813 / 1819
页数:7
相关论文
共 50 条
  • [31] Melittin Treats Periprosthetic Osteolysis in a Rat Model by Inhibiting the NF-kB Pathway and Regulating the Ratio of Receptor Activator of Nuclear Factor Kappa B Ligand/Osteoprotegerin
    Niu, Junqi
    Bi, Fanggang
    Tian, Qing
    Tian, Ke
    JOURNAL OF ARTHROPLASTY, 2024, 39 (07): : 1845 - 1855
  • [32] Assessment of receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in lymphoma patients
    Ayoub, M.
    Gadallah, H.
    Hegab, H.
    Khattab, D.
    Mostafa, N.
    EJC SUPPLEMENTS, 2010, 8 (04): : 22 - 22
  • [33] Differential expression of receptor activator of nuclear factor kappa B ligand and osteoprotegerin in calcific aortic stenosis
    Kaden, JJ
    Bickelhaupt, S
    Kilic, R
    Sarikoc, A
    Lang, S
    Haase, KK
    Dempfle, CE
    Borggrefe, M
    EUROPEAN HEART JOURNAL, 2003, 24 : 149 - 149
  • [34] IDENTIFICATION OF RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-kappa B LIGAND(RANKL) AND OSTEOPROTEGERIN(OPG) IN AMELOBLASTOMA
    Ha, Woo-Hun
    Hwang, Dae-Seok
    Kim, Yong-Deok
    Shin, Sang-Hun
    Kim, Uk-Kyu
    Kim, Jong-Ryoul
    Chung, In-Kyo
    JOURNAL OF THE KOREAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS, 2007, 33 (02) : 94 - 102
  • [35] Cementocytes Express Receptor Activator of the Nuclear Factor Kappa-B Ligand in Response to Endodontic Infection in Mice
    De Rossi, Andiara
    Fukada, Sandra Yasuyo
    De Rossi, Moara
    Bezerra da Silva, Raquel Assed
    Queiroz, Alexandra Mussolino
    Nelson-Filho, Paulo
    Bezerra da Silva, Lea Assed
    JOURNAL OF ENDODONTICS, 2016, 42 (08) : 1251 - 1257
  • [36] Rheumatoid synovia cause bone destruction via receptor activator of nuclear factor KAPPA-B ligand
    Kuga, Y
    Taniguchi, K
    Uchida, S
    Uchida, T
    Uzuki, M
    Sawai, T
    Miller, D
    Oda, H
    Nakamura, K
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 375 - 375
  • [37] Fracture risks and their mechanisms in atopic dermatitis, focusing on receptor activator of nuclear factor kappa-B ligand
    Sakai, Takashi
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (11) : 1209 - 1213
  • [38] The Effect of Osteoprotegerin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) on Aortic Valve Calcified
    Luo, Wei
    Wang, Jing
    Yang, Xia
    Li, Junshan
    Song, Yanqiu
    Cong, Hongliang
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2024, 54 (05): : 633 - 642
  • [39] Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway
    Kondegowda, Nagesha Guthalu
    Fenutria, Rafael
    Pollack, Ilana R.
    Orthofer, Michael
    Garcia-Ocana, Adolfo
    Penninger, Josef M.
    Vasavada, Rupangi C.
    CELL METABOLISM, 2015, 22 (01) : 77 - 85
  • [40] Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
    Vachliotis, Ilias D.
    Polyzos, Stergios A.
    CURRENT OBESITY REPORTS, 2023, 12 (02) : 147 - 162